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Fibrinolysis and beyond: bridging the gap between local  
and systemic clot removal
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Recanalization methods in ischemic stroke have been progressively expanded over the past years. 
In addition the continuous development of specialized mechanical devices for thrombectomy 
a broad spectrum of new drugs has been tested: Both options, novel drugs as well as new 
devices, can be employed independently of each other, but in most cases a combination of the 
two with the standard treatment of intravenous fibrinolysis is applied. Until recently, a large 
number of case series have been performed to investigate the effects of various drugs and 
interventions, but only a few trials have been conducted to determine the optimal conditions 
for combining both procedures. This review surveys the different systemic and endovascular 
vessel reopening practices and their major bridging techniques.
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processing IAT and/or mechanical intra-arterial   procedures. Yet 
despite a considerable number of different techniques the opti-
mal crossover between intravenous and intra-arterial measures 
is still unavailable. Here we summarize the current data for the 
major recanalization-techniques and the various options for 
combining them. Finally, we propose a protocol for an actual 
bridging practice.
Intravenous thrombolysIs
Intravenous recombInant tIssue-type plasmInogen 
actIvator
After a number of studies involving intravenous application of 
streptokinase  attempted  to  resolve  the  therapeutic  nihilism  in 
ischemic stroke (MAST-I, 1995; Donnan et al., 1996; MAST-E, 
1996), the NINDS-study group, in 1995, published their landmark-
findings from a study of 624 patients with acute ischemic stroke 
(National Institute of Neurological Disorders, and Stroke rt-PA 
Stroke Study Group, 1995). In this study patients received 0.9 mg/
kg/body weight (BW) of alteplase within 3 h of symptom onset. 
Patients in the treatment group were at least 30% more likely to 
have minimal or no disability at 3 months than those who received 
a placebo.
By comparison, two European trials: the European Cooperative 
Acute Stroke Study I (ECASS I) and ECASS II, investigated a time 
window of up to 6 h but failed to show the efficacy of thrombo-
lytic treatment, as defined by each trial (Hacke et al., 1995, 1998). 
Nevertheless, the results from an extensive review (Wardlaw et al., 
2003) of 18 fibrinolytic trials suggested a positive effect for rtPA 
given up to 6 h. Furthermore, a pooled analysis of the common data 
elements from six randomized placebo-controlled trials, including 
ATLANTIS (Part A and B), ECASS (both trials), and NINDS (Part 
1 and 2) which investigated thrombolysis with rtPA for ischemic 
stroke,  reported  favorable  outcomes  even  when  therapy  was 
administered between 3.0 and 4.5 h after symptom onset (Hacke 
et al., 2004). In 2008, the ECASS-3 trial confirmed this finding 
(Hacke et al., 2008).
background and purpose
Reperfusion is the primary therapeutic goal during acute ischemic 
stroke. By restoring blood flow to the affected vessel, reperfusion 
therapies save penumbral tissue, reduce final infarct size and 
result in an improved clinical outcome. The standard reperfusion 
method  –  intravenous  recombinant  tissue-type  plasminogen 
activator (I.V.-rtPA) is the quickest way to initiate thrombolysis 
for acute ischemic stroke. At present treatment is recommended 
within the first 3 h after symptom onset, but the time window can 
be extended to 4.5 h based on the increasing evidence of benefit in 
patients treated within this interval (Hacke et al., 2008; Wahlgren 
et al., 2008). The effect of fibrinolysis depends chiefly on reca-
nalization, which increases the probability of a favorable clinical 
outcome by a four- to fivefold factor. Intravenous fibrinolysis 
however reopens an occluded vessel in less than half of all cases 
(Rha et al., 2007). Moreover it recanalizes only one out of three 
patients with an occlusion of the proximal middle cerebral artery 
and only about one out of 10 patients in cases of thrombosis 
of the internal carotid artery (ICA; Mori et al., 1992; Wolpert 
et al., 1993; Tomsick et al., 1996; IMS Study Investigators, 2004). 
Therefore, particularly the prognosis of patients with clinically 
severe ischemic strokes caused by occlusions in the proximal 
vascular bed remains relatively poor. In these cases endovascu-
lar methods clearly provide higher recanalization rates at the 
expense of a longer delay in treatment initiation. The time to 
recanalization however is in itself a very substantial predictor 
of clinical outcome (Ringelstein et al., 1992; Heiss et al., 1998; 
Christou et al., 2000). Thus procedures such as intra-arterial 
thrombolysis  (IAT)  and  mechanical  thrombectomy  improve 
recanalization rates considerably, but there is substantial doubt 
with regard to the ultimate superiority of their clinical efficacy. To 
avoid low recanalization rates by I.V.-rtPA or delayed reopening 
by IAT a bridging approach of both methods is more auspicious 
than one single method in isolation. The combination of both 
methods provides the advantages of early treatment initiation via 
I.V.-rtPA as well as higher recanalization rates by subsequently 
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escalation of desmoteplase for acute ischemic stroke trial (DEDAS), 
based on the same study protocol as the previous study, corrobo-
rated these findings (Furlan et al., 2006). However the consecutive 
follow-up trial DIAS II (Hacke et al., 2009) did not confirm the 
benefit by DSPA. It has been speculated that this was attributable 
to an uncommon spontaneous reopening rate of 50% in the pla-
cebo group, but the exact reasons for the discordant result are still 
unknown. Meanwhile a third DIAS-trial is on the way.
Similar  to  DSPA,  ancrod,  a  substance  which  induces  rapid 
defibrinogenation in humans by splitting fibrinopeptide A from 
fibrinogen, is derived from a non-human source. The purified frac-
tion of the venom of the Malaysian spit viper has been investigated 
in acute ischemic stroke and has produced favorable outcomes in 
an initial randomized, placebo-controlled study (Sherman et al., 
2000), in which 500 patients with an acute ischemic stroke were 
treated with ancrod versus a placebo. However several consecutive 
trials, in which ancrod was administered within a 3- or 6-h window, 
revealed inconsistent results. Finally Levy et al. (2009) failed to 
show an improvement in outcome in 500 randomized patients in 
the ASP-study, even after adjusting the timing and dosage regimes 
to the experiences of the preceding studies, and there was also still 
a trend to increased bleeding rates.
glycoproteIn IIb/IIIa antagonIsts – abcIxImab, tIrofIban, and 
eptIfIbatIde
The glycoprotein (GP) IIb/IIIa complex is the major integrin 
present on the platelet surface and plays a key role in platelet 
aggregation. The use of GP-IIb/IIIa antagonists is widespread and 
very common for cardiological purposes because of its efficacy in 
coronary interventions (Cura et al., 2000). Whereas Eptifibatide 
and Tirofiban as separate treatment options for ischemic stroke 
have only been investigated in retrospective case series (Martin-
Schild et al., 2009) or in case reports (Liebeskind et al., 2002), 
Abciximab, the recombinant Fab fragment of a monoclonal anti-
GP-IIb/IIIa antibody has been investigated more extensively. After 
encouraging Phase I and II trials (Abciximab in Ischemic Stroke 
Investigators, 2000; Abciximab Emergent Stroke Treatment Trial 
(AbESTT) Investigators, 2005) in ischemic stroke that demon-
strated a trend toward better clinical outcomes without increas-
ing hemorrhagic complications, a phase III trial was initiated 
(Adams et al., 2008). In addition to a cohort of patients within 
6 h after stroke onset, a special cohort with “wake up strokes” was 
included. The clinical outcome was determined 3 months after 
admission using the mRS and the results were disappointing: 
whilst there was no difference in terms of good clinical outcome 
(33% of placebo-treated patients versus 32% of abciximab-treated 
patients), the rate of symptomatic or fatal intracranial hemor-
rhage increased significantly from 0.5% in the placebo group to 
5.5% via inhibition of the GP-IIb/IIIa complex. As a result, the 
trial was terminated prematurely. In an alternative approach the 
CLEAR trial tested the combination of GP-IIb/IIIa-inhibitors, 
namely eptifibatide (75 μg/kg/BW bolus followed by a 0.75-μg/
kg/BW/min infusion for 2 h), with a low dose rtPA regimen of 
either 0.30 mg/kg or 0.45 mg/kg/BW. The results were compared 
to a standard dose rtPA treatment (0.9 mg/kg; Pancioli et al., 
2008). This approach appeared to be safe, but reports of a   clinical 
  amelioration are still lacking.
In ECASS I, using 1.1 mg/kg/BW rtPA, resulted in a substantial 
number of intracranial hemorrhages, whereas most of the other 
randomized trials used 0.9 mg/kg/BW rtPA. On the other hand a 
lower dosage of rtPA may prove to be comparably effective. Two 
recent Japanese trials have shown that in an Asian population a 
similar outcome may be reached by two thirds of the standard 
rtPA  dose  in  Caucasians  (Yamaguchi  et  al.,  2006;  Mori  et  al., 
2010). Meanwhile, the dosage of 0.9 mg/kg/BW has not only been 
proved to be safe in randomized trials but also in clinical practice 
as shown in a large register with 6483 patients (Wahlgren et al., 
2007). At present I.V. thrombolysis with 0.9 mg/kg/BW rtPA has 
been approved in most countries.
Nevertheless even in industrialized countries only the minority 
(Katzan et al., 2004; Albers and Olivet, 2007) of all ischemic stroke 
patients receives rtPA therapy. The major reason for its restricted 
application is its reportedly narrow time window (Lees et al., 2006; 
Harrer, 2010), compounded by the necessity of cerebral imag-
ing to exclude intracerebral hemorrhage. Since the late 1990’s 
(Schlaug et al., 1999), there have been attempts to prolong this 
short therapeutic interval by implementing an approach to predict 
the clinical success of recanalization by imaging the penumbra 
via the so-called “diffusion–perfusion mismatch.” Particularly in 
cases of proximal artery occlusion screening for this mismatch 
may help to increase the proportion of patients eligible for throm-
bolysis and as many as 70–80% show potentially salvageable tissue 
for more than 9 h (Copen et al., 2009). Although several phase 
II-studies (Hacke et al., 2005; Albers et al., 2006; Furlan et al., 
2006) and a retrospective analysis of ATLANTIS, ECASS, and 
NINDS (Thomalla et al., 2006) have confirmed this concept, a 
prospective Phase 3 study that used this approach (Hacke et al., 
2009) failed to demonstrate any benefit.
other fIbrInolytIcs
Because of the disadvantages associated with rtPA there have been 
numerous attempts to find alternative fibrinolytic agents with a 
longer half life and a higher fibrin specificity to facilitate the appli-
cation, to decrease the rates of hemorrhage, and to optimize the 
therapeutic effects. Tenecteplase, another plasminogen activator 
which can be administered in a bolus form has been investigated 
in two phase II trials (Haley et al., 2005, 2010). Both trials, however 
ended more or less at the dose finding level without demonstrating 
superiority or even equivalence to rtPA. Desmoteplase (DSPA), 
originally isolated from the saliva of a vampire bat, is a highly 
fibrin-specific plasminogen activator. Treatment with DSPA is of 
particular interest for thrombolysis after the 3-h time window 
owing to its potential to reduce intracranial hemorrhaging. In 2005, 
findings of the desmoteplase in acute ischemic stroke trial (DIAS 
I) in which I.V. DSPA was administered within 3–9 h of ischemic 
stroke onset in patients with perfusion/diffusion mismatch on MRI, 
were published (Hacke et al., 2005). One hundred and four patients 
with a National Institute of Health Stroke Scale (NIHSS) score of 
4 to 20 were included. Outcome was rated by reperfusion on MRI 
4–8 h after treatment, and clinical improvement after 3 months was 
assessed by using the NIHSS, the modified ranking scale (mRS), and 
Barthel index (BI). A significant advantage was found in terms of 
clinical as well as imaging parameters for DSPA, with the best results 
in the 125-μg/kg/BW group. A year later, the results of the dose www.frontiersin.org  February 2011  | Volume 2  | Article 7  |  3
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The absolute benefit was 15% and the relative benefit 58%. Within 
the last 15 years however only one further randomized trial of 
intra-arterial fibrinolysis (Ogawa et al., 2007) in ischemic stroke has 
been performed. Trials based on directly comparing intra-arterial 
and intravenous thrombolysis in terms of recanalization rates and 
especially in terms of clinical outcome have not been performed at 
all. Thus, intra-arterial fibrinolysis remains an individual treatment 
approach without approval by the FDA and it is not recommended 
generally.
mechanIcal thrombectomy
As an alternative to or as a supplementary tool for systemic or IAT 
mechanical thrombectomy provides higher recanalization rates – 
particularly in patients with occlusion of the carotid-, proximal 
media- or basilaric-artery. Endovascular thrombectomy devices 
remove the occluding clot from the affected vessel mechanically. In 
general three systems can be distinguished: initially distal systems 
have been developed, which permit retrieval of the clot by remov-
ing the thrombus on the way back after the thrombus has been 
passed by the system. A typical device is the mechanical embolus 
removal in cerebral ischemia (MERCI) Retrieval System. Results 
of the Phase 1 MERCI trial were published in 2004 (Gobin et al., 
2004). In this study 28 patients with ICA, MCA, or occlusions of 
the basilar artery were treated within a median time of 6.15 h. In 
43% of all patients, an effective recanalization could be achieved. 
No clinically significant bleeding occurred. Four years later, the 
final data of the Multi MERCI trial, a study with approximately the 
same inclusion criteria as the previous study but with treatment 
within 8 h, were released (Smith et al., 2008). One hundred and 
sixty-four patients were enrolled, and 131 were initially treated 
with the newer generation of MERCI L5 retriever. Recanalization 
by pure mechanical thrombectomy was achieved in 57.3%, whereas 
a recanalization rate of 68% was achieved after additional IAT. Even 
more importantly, the clinical outcome after 90 days was signifi-
cantly (p < 0.001) improved. In turn, this clinical improvement 
correlated closely with success rates of recanalization. A pooled 
analysis of MERCI and Multi MERCI with a subinvestigation of 
patients with an acute stoke from intracranial ICA-occlusion con-
firmed this observation (Flint et al., 2007). Because of its promising 
results the MERCI Retriever was the first FDA-approved technical 
device used to restore blood flow.
Alternatively to this method, a clot may be removed from the 
proximal side, e.g., by using aspiration techniques. In the process, 
the necessity of perforating the thrombus can be avoided, thereby 
reducing the risk of thrombus fragmentation and associated distal 
emboli. However a comparison of both methods (i.e., retrieval 
versus aspiration) reveals a higher recanalization rate for the distal 
thrombectomy systems (Gralla et al., 2006; see Table 1).
An even more advanced device is the Penumbra Stroke System, 
which was licensed by the FDA after it achieved a recanalization 
rate of 100% in a smaller pilot study (Bose et al., 2008) and even 
81.6% in a subsequent larger prospective trial (Penumbra Pivotal 
Stroke Trial Investigators, 2009). In addition to an aspiration sys-
tem, this device includes a mechanism for grasping the thrombus 
directly. In a similar manner, stents like the Solitaire-remodeling 
device, are capable of being delivered immediately to the side of 
the thrombus and removing the clot, while at the same time, being 
I.a.-thrombolysIs (Iat)
In IAT fibrinolytic drugs are applied directly into the occluding 
thrombus using microcatheter delivery systems. By means of this 
minimally invasive technique high local drug concentrations with 
lower systemic concentrations can be achieved, which, at least theo-
retically, reduces the risk of extracranial hemorrhagic complications. 
In addition this method provides precise imaging of the arterial 
anatomy, pathology, and collateral circulation. Furthermore, IAT 
includes the option of applying additional devices to disrupt the 
clot mechanically. In retrospective clinical case studies, IAT yielded 
higher rates of recanalization than I.V. therapy (Alexandrov et al., 
2002; Higashida et al., 2003), with an estimated average recanaliza-
tion rate of 70%, which has been confirmed in a recent meta-anal-
ysis (Lee et al., 2010). The method’s chief disadvantage, however, is 
the lag time during which fibrinolysis is initiated. The delay can be 
attributed to logistic as well as procedure-related technical reasons 
and is closely related to the progression of neuronal cell death in the 
ischemic brain, which has been shown to be strictly time dependent. 
Moreover the most effective thrombolytic drug for IAT has never 
been adequately tested. Although in the prolyse in acute cerebral 
thromboembolism (PROACT)-trials recombinant prourokinase 
has been used, r-proUK is unavailable routinely because it lacks 
FDA approval. As such, most recent investigations have utilized 
rtPA for practical reasons. Additionally, the ideal dosage for both 
drugs in IAT has not been tested. Patients were treated with either 
urokinase in a dosage up to 2 million U or with rtPA in a dosage 
up to 90 mg within 6 h of symptom onset. Comparisons between 
these trials are complicated because of the broad range of inclu-
sion and exclusion criteria. The PROACT I study in 1995 was the 
first randomized double-blinded multicenter trial, in which safety, 
recanalization frequency, and clinical efficacy of IAT with r-proUK 
were compared with a placebo in patients with symptomatic MCA 
occlusion in a 6-h time window (del Zoppo et al., 1998). Eligible 
patients were randomized to receive a placebo or a fixed dose of 
6 mg r-proUK administered over a 2-h period in the proximal 
third of the thrombus or close to the clot within the M1-segment. 
Mechanical disruption of the thrombus was prohibited. The degree 
of the recanalization was determined at the end of the procedure. 
Subsequently, patients were given I.V. heparin for 4 h. Because of 
severe hemorrhage rates in the first 16 patients with a high dose 
heparin regime, the heparin dose was later decreased. A CCT was 
performed in all patients after 24 h to control bleeding. Clinical 
outcome was rated by blinded physicians by the NIHSS, the mRS, 
and the BI 7, 30, and 90 days after treatment. Out of 40 patients, 
26 received r-proUK, and 14 a placebo. In summary, there was 
a  10–12%  absolute  increase  in  positive  outcomes  in  patients 
treated with r-proUK compared to those in the placebo group. 
Interestingly, heparin reduction resulted in a decreased recanali-
zation rate from 82 to 40%, and, at the same time, hemorrhagic 
side-effects were also lower. The rate of symptomatic bleedings was 
15% in the r-proUK group compared to 7% in the placebo group. 
Consequently in PROACT II (Furlan et al., 1999) the dosage of 
r-proUK was increased to 9 mg to improve the recanalization rates 
whereas only low dose heparin was administered. One hundred 
and eighty patients were randomized and 121 patients received 
r-proUK. Under this regimen, recanalization rate was 66% with an 
symptomatic hemorrhage rate of 10% for r-proUK treated patients. Frontiers in Neurology  | Endovascular and Interventional Neurology    February 2011  | Volume 2  | Article 7  |  4
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management of stroke single arm trial (IMS I) from 2004 (IMS 
Study Investigators, 2004). In this study the same I.V.-rtPA dosage 
was used, but the initial I.V.-bolus was slightly increased to 15% 
and the consecutive intra-arterial dosage was adapted to 22 mg 
rtPA. The 3-months outcome in these 80 subjects was matched to 
the outcome in the NINDS rtPA Stroke trial thus making it pos-
sible to compare standard intravenous fibrinolysis (I.V.-rtPA) with 
the I.V./I.A.-approach. Once again the asymptomatic hemorrhage 
rates increased significantly with the combination therapy (43 ver-
sus 6%), whereas symptomatic bleedings did not differ in between 
these two trials. The clinical outcome of the combined therapy did 
not differ from the purely intravenous procedure, although both 
methods substantially improved the clinical outcome compared to 
the placebo-treated patients in NINDS. In the subsequent single 
arm Interventional Management of Stroke II Study (IMS II Trial 
Investigators, 2007), 81 subjects with even more severe strokes 
and a median baseline NIHSS score of 19 were included. Fifty-five 
patients received the combined I.V./IAT. The results were similar to 
the IMS I trial with a mRS of 0–2 in 46% after 3 months, but the 
rate of symptomatic intracranial hemorrhages was increased from 
6.3 in IMS I to 9.9% in IMS II. Nonetheless, it should be borne in 
mind that in the 2007 study, in 36 of the 55 I.A.-treated patients the 
approach was complemented by a small-vessel ultrasound infusion 
system (EKOS) to potentially accelerate thrombolysis. In a more 
clinical setting the “classical” bridging-version has been tested in 
both carotid artery distribution strokes (Ernst et al., 2000) and in 
very severely affected patients (Zaidat et al., 2002). In the event of 
persisting deficits, the I.V.-approach was shifted after 30 min to a 
IAT until the clot completely resolved or up to a maximum dosage 
of 0.9 mg/kg/BW. Although a recanalization could be achieved in 
four out of five patients with an ICA-occlusion, the mortality rate 
remained as high as 50%. Interestingly, an upside-down pathway has 
also been conducted. Keris et al. (2001) applied primarily IAT fol-
lowed by I.V.-thrombolyis. In that study 45 patients with severe acute 
ischemic stroke within 6 h after symptom onset were investigated. 
Only 12 of them were randomized to the fibrinolysis group, whereas 
completely retrievable (Henkes et al., 2003; Castano et al., 2009b). 
Although only small case series are available, the Solitaire stent 
might be superior (Castano et al., 2009b) to distal retraction devices 
owing to its simplicity and speed, as well as its relatively protective 
properties for the vessel wall. In any event, a comparison of several 
recanalization procedures (Rha et al., 2007; Nogueira et al., 2009) 
and thrombectomy devices (Castano et al., 2009a, Serna-Candel 
et al., 2010) yields the highest recanalization success rates for distal 
thrombectomy devices, one the one hand, and the Solitaire stent 
on the other (see Table 1).
brIdgIng therapy
I.v./I.a.-combInIng I.v. and I.a.-rtpa
Time delay resulting from initiation and preparation of IAT and 
mechanical devices is the main drawback of this technique com-
pared with I.V. thrombolysis.
A potential advantage of a combined I.V./I.A. approach is the rapid 
initiation and easy handling of I.V. treatment, combined with the 
potentially higher recanalization rates associated with I.A. therapy, 
to optimize clinical outcome. Lewandowski et al. (1999) published 
the findings of the emergency management stroke (EMS) Bridging 
Trial. This was a double-blinded, randomized, placebo-controlled 
multicenter trial that compared pure IAT to an I.V./I.A. approach. A 
total of 35 patients with acute ischemic stroke within 3 h after symp-
tom onset were randomized. They received either a loading dose of 
0.6 mg/kg/BW I.V. rtPA with 10% as bolus application (17 patients) 
or a placebo (18 patients) followed immediately by cerebral arte-
riography and local I.A.-rtPA with a maximal dose of 20 mg rtPA. 
The combined approach yielded significantly higher recanalization 
rates (55% I.V./I.A. versus 10% placebo/IAT) without producing a 
clinically significant improvement as measured by NIHSS, BI, mRS, 
and Glasgow Outcome Scale at days 1 and 7 and after 3 months. 
The obviously higher mortality rate in the I.V./I.A.-group seemed 
to be attributable to the very low numbers of patients included. In 
a very similar (but not placebo-controlled) approach, 80 severely 
affected patients (NIHSS ≥ 10) were treated in the   interventional 
Table 1 | Recanalization rate upon different procedures.
Recanalization method  n (pts.)   Recanalization  Patients with   Studies/references 
     rate in %  ICA-occlusions in %
Spontaneous (placebo)  253  24.1  NA  Rha et al. (2007)
I.V.  474  46.2  NA  Rha et al. (2007)
I.V. + tUS  63  46  0  Alexandrov et al. (2004)
Bridging  95  52.6  20.5  IMS II Trial Investigators (2007, parts);  
       IMS Study Investigators (2004);  
       Lewandowski et al. (1999)
Bridging + eUS  33  72.7  NA  IMS II Trial Investigators (2007, parts)
I.A. (rp)UK  165  67.3  0  Furlan et al. (1999); Ogawa et al. (2007)
MERCI + I.A. rtPA  164  68.2  30  Smith et al. (2008)
Penumbra  125  81.6  18  Penumbra Pivotal Stroke
       Trial Investigators (2009)
Solitaire AB  20  90  40  Castano et al. (2009a)
tUS, transcranial ultrasound; eUS, endovascular ultrasound; NA, not applicable. Due to the importance of the proximal occlusion site, the percentage of ICA-occlusion 
is separately listed. Recanalization is due to a grading of two or three in the thrombolysis in myocardial infarction (TIMI) or thrombolysis in cerebral infarction (TICI) 
score beside Alexandrov et al., (2004), who used the thrombolysis in brain ischemia (TIBI) classification.www.frontiersin.org  February 2011  | Volume 2  | Article 7  |  5
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fibrinolytic dosages compared to the PROACT and IMS-1 and -2 tri-
als. Unfortunately the results of the randomized IMS-3 trial (Khatri 
et al., 2008), which includes the use of two different catheter devices, 
will be a long time in coming.
conclusIon
At present, intravenous fibrinolysis is the approved standard therapy 
in patients with acute ischemic stroke. Nevertheless, only a minority 
of all patients is treated with I.V.-rtPA, whereas recanalization – 
the most crucial factor for the clinical outcome – succeeds in only 
50% of patients receiving this therapy. Intra-arterial procedures 
yield considerably higher recanalization rates for I.A.-rtPA and 
particularly for mechanical thrombectomy devices, although their 
clinical superiority over the systemic approach may depend on the 
time lag associated with the more complex technique. Accordingly, 
bridging this time lag by means of intravenous rtPA is a useful 
strategy. Most available data from randomized trials recommend 
a dosage of 0.6 mg/kg/BW rtPA and a time lag of 30 min as “intra-
venous to intra-arterial” needle time (Lewandowski et al., 1999; 
Ernst et al., 2000; Zaidat et al., 2002; IMS Study Investigators, 2004; 
IMS II Trial Investigators, 2007). Although superior clinical out-
comes have not been proved yet, this regimen seems to be reason-
able. Treatment confined to a dosage of 0.6 mg/kg/BW I.V.-rtPA is 
effective, at least in an Asian population (Yamaguchi et al., 2006; 
Mori et al., 2010), whereas the incidence of intracranial hemor-
rhages remains unchanged even when intra-arterial fibrinolysis 
is also performed. The 30-min time lag between I.V.-rtPA and the 
initiation of intra-arterial procedures is short, but this interval has 
to be as short as possible. In the event that, for logistical reasons, 
it is necessary to exceed the 30-min time limit, an intravenous 
fibrinolysis with 0.9 mg/kg/BW rtPA should be administered. The 
data to date in the field (Flint et al., 2007; Shaltoni et al., 2007) does 
not indicate that there are higher symptomatic bleeding rates if an 
intra-arterial procedure is performed immediately after a full dose 
I.V.-rtPA fibrinolysis.
In  general  subsequent  endovascular  intervention  should  be 
aimed at recanalizing persisting vessel-occlusions, as performed 
in several recent studies (Eckert et al., 2005; Mangiafico et al., 2005; 
Flint et al., 2007; Smith et al., 2008; Castano et al., 2009a; Mazighi 
et al., 2009). Depending on the preceding intravenous rtPA dos-
age, we propose a strategy based predominantly on a combination 
of an intra-arterial fibrinolysis and a mechanical device after an 
intravenous dosage of 0.6 mg/kg/BW rtPA, whereas a almost “pure” 
mechanical  intervention,  for  example  with  the  Solitaire  stent, 
should be preferred following an intravenous full dose rtPA regi-
men. However, in our experience recanalization by an I.A. approach 
without any additional fibrinolytic agent is difficult. Therefore a 
small amount of rtPA is always used in our center.
Finally, all these approaches have to be able to demonstrate 
their clinical superiority when comparing their results with the 
gold standard, which up to now remains I.V.-rtPA. Therefore a 
randomized trial comparing intravenous fibrinolysis with a bridg-
ing therapy is desperately needed. In this study patients with a 
proximal artery occlusion and a large penumbra according to the 
MRI mismatch criteria should be treated either intravenously or 
by a bridging regimen, including intra-arterial fibrinolysis and/or 
mechanical thrombectomy.
33 patients were randomized to the conventional treatment group. 
Patients in the first group received 25 mg rtPA I.V. over 60 min after 
an intra-arterial injection of 25 mg rtPA over 5–10 min without 
mechanical clot disruption. Although clinical outcomes following 
treatment assessment at 1 and at 12 months were better, these results 
are clearly restricted by the very low number of patients studied.
brIdgIng extended – I.v./I.a-thrombolysIs and beyond
Despite inconclusive results and an astonishing lack of even a single 
study comparing a combined I.V./I.A. approach to the standard 
I.V.-rtPA scheme in a randomized trial, the “conventional” I.V./I.A.-
combination approach has been extended in several ways. Some 
investigators used urokinase (UK) in addition to rtPA for synergis-
tic and complementary effects. For example, in 24 patients with a 
median baseline NIHSS score of 18, Lee et al. (2004), administered 
a full dose I.V.-rtPA (0.9 mg/kg/BW) treatment followed by I.A. UK 
(300000 U initially, with a maximum overall dose of 1000000 U). 
Symptomatic hemorrhage rates remained low, although four patients 
also received I.V. abciximab when a reocclusion of the affected ves-
sel was identified (Lee et al., 2004). In general, many studies have 
supplemented rtPA or UK with GP-IIb/IIIa-inhibitors. Eckert et al. 
(2005) combined I.V. abciximab (0.25 mg/kg bolus, followed by a 
12-h infusion therapy with 0.125 μg/kg/min) with IAT (median dos-
age: 20 mg rtPA) in patients with basilar artery stroke. I.V. tirofiban 
combined with I.A. UK was studied by Mangiafico et al. (2005) – this 
time again in severely affected patients with a median NIHSS score of 
21. The outcome after 3 months was compared with a retrospective 
cohort treated with I.A.-rtPA (median dosage: 40 mg). In view of 
the small numbers of subjects enrolled in these studies, definitive 
clinical conclusions cannot yet be drawn. It needs to be pointed out 
however, that despite a higher degree of hemorrhaging in general no 
significant differences in symptomatic bleedings have to be toler-
ated. This is also true when mechanical procedures are added to the 
pharmacological approach to enhance recanalization. Typically such 
protocols are gradated constructs, adding intra-arterial fibrinolysis, 
and mechanical procedures in the event of persistent occlusion after 
the preceding intravenous intervention. In 2009, the RECANALISE 
study (Mazighi et al., 2009) achieved a recanalization rate of 87% 
in this manner, although one fourth of the study population of 
more than 50 individuals in the I.V./endovascular approach had 
combined ICA/MCA-occlusions. Three years previously, the Multi 
MERCI Trial (Flint et al., 2007) had yielded a similarly high rate 
of effectiveness in a very similar group. Nevertheless, comparison 
with the pure intra-arterial PROACT II study did not reveal the 
superiority of this combined approach (Josephson et al., 2009) in 
terms of clinical outcome. It is worth mentioning that in the Multi 
MERCI trial, unlike the RECANALISE study, a full dose of I.V. fibri-
nolysis (0.9 mg/kg/BW) was administered. Intuitively, this regimen 
seems to be more prone to intracranial hemorrhages. In contrast, 
Shaltoni et al. (2007), in a retrospective data set from 69 patients 
with a median pretreatment NIHSS score of 18, showed that a con-
secutive IAT within a median time of 105 min after finalizing a full 
dose I.V.-treatment did not necessarily result in higher symptomatic 
intracranial hemorrhage rates. However, a direct comparison of 
the intracranial hemorrhage frequencies is difficult, as this study 
included mainly intra-arterial treatment with reteplase. Moreover 
the few patients treated with alteplase and UK received even lower Frontiers in Neurology  | Endovascular and Interventional Neurology    February 2011  | Volume 2  | Article 7  |  6
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